GI medical oncologist focusing on stomach and esophageal cancer research at Massachusetts General Hospital, Harvard Medical School
Boston, MA
Joined January 2019
- Tweets1.1K
- Following686
- Followers5.1K
- Likes2.9K
Pinned Tweet
Check out our deep dive in MSI-H gastric cancer, now out in @CD_AACR . Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer cancerdiscovery.aacrjournals…
Sam Klempner retweeted
CLARITY- Gastric 01 (CG-01) Phase III AZD-0901 (Sone-Ve) in 2L+ met #Claudin 18.2 (+) in #Gastroesophageal #cancer vs. investigators choice (N=594)
Primary endpoints: PFS + OS
🔹OS: 10M vs. 5M (HR = 0.47) 👏
🔹12M OS: 38.1% vs. 18.1%, HR = 0.47 (3rd line)
🔹 12M 42.6% in 2nd line
🔹 ORR: 23.3% vs. 13.8%
🔹PFS: HR = 0.77 was NS in 2L+
🔹PFS: HR = 4.1 vs. 2.7M; HR = 0.56 in 3L+
🔹Need more data in the 2L setting; largest benefit seen in 3L+ setting
#ESMO2026 @OncoAlert #cancerresearch @AstraZeneca
Cover of @SciImmunology. Led by @sm_blum and team @MassGenBrigham. Very fun project and lots to do. @villanilab @sundar__raghav @boehmjesse
Multiomic analysis of malignant ascites defines RORC-expressing dendritic cells at sites of metastasis
science.org/doi/10.1126/scii…
Sam Klempner retweeted
Celebrating our notification of award for our new P01 studying mechanisms of resistance to chemoradiation in GI cancers. Excited to get to work with Co-PI @KlempnerSam and the rest of the incredible team @DanaFarber @MassGenBrigham @BIDMC_CancerCtr
@MGBResearchNews @harvardmed
Sam Klempner retweeted
📢FDA approval of zanidatamab + chemotherapy ± tislelizumab in the 1L setting represents an important advance and ushers in a new era for HER2-directed therapy in GEA.
Congratulations to the investigators, patients, and teams who made this possible! #GastricCancer #HER2 #GIOnc
Always fun to write with @sundar__raghav. In @MedCellPress. Reprogramming HER2-Positive gastroesophageal cancer immune contexture with bispecific therapy: HERIZON-GEA-01: Med cell.com/med/fulltext/S2666-…
Now online @CellRepMed and led by talented grad student Sam Wright. Team effort with @JeeyunM @AnMinae @arnavmehta3 @getz_lab and Ryan Park lab.
We examine T cell clonal dynamics during frontline chemoimmunotherapy in advanced gastric cancer
cell.com/cell-reports-medici…
Not possible without support from @SU2C and Torrey Coast Foundation. @MassGenBrigham
In the @NEJM, hidden in the #ASCO26 flurry, is our letter highlighting response to first-in class approach to directly targeting beta-catenin:TCF interaction
Targeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastoma | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
Sam Klempner retweeted
Thrilled to share phase 3 HERIZON-GEA-01 in @NEJM before @ASCO. Biparatopic anti-HER2 Zanidatamab plus chemo±tislelizumab improved PFS in HER2+ gastric/GEJ cancer; the tislelizumab combo also improved OS. Grateful to all patients and collaborators.
nejm.org/doi/full/10.1056/NE…
Now out online in @Cancer_Cell . Fun writing this with @sundar__raghav and talented student Luke Tillman and other.
Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation: Cancer Cell cell.com/cancer-cell/fulltex…
Sam Klempner retweeted
Delighted to share results of phase 2 ILUSTRO in @NatureMedicine @KlempnerSam @ASCOPost Zolbetuximab+FOLFOX+nivo showed encouraging activity in CLDN18.2+ gastric cancer with mPFS 14.8 months (18months in high CLDN). Supporting the ongoing phase 3 LUCERNA.
doi.org/10.1038/s41591-026-0…
Looking beyond Claudin18.2 in solid tumors. @NatureRevCancer
doi.org/10.1038/s41568-026-0…
How low can you go? Looking at broader CLDN18.2 cutoffs in GC/GEJ. Nice work from visiting researcher from Korea, courtesy of @JeeyunM @myESMO
sciencedirect.com/science/ar…
Congratulations to the Matterhorn study team. FDA approval independent of PD-L1 status.
fda.gov/drugs/resources-info…
With interest in PD-1xVEGF across cancers we add some data from Ram and Pembro. @CIR_AACR @JeeyunM @AnMinae @arnavmehta3
Distinct spatially resolved TME trajectories define benefit from ramucirumab + pembro in refractory PD-L1+ gastric cancer aacrjournals.org/cancerimmun…
Now out in @NatureComms. Led by Dr. Liz Carstens in Eric Smith lab @DanaFarber. Modeling on-target/off-tumor tox in CLDN18.2 directed therapy. @KoheiShitara @jonathan_nowak. Supported by @DeGregorioFF.
rdcu.be/eN4cg
Sam Klempner retweeted
📢 Ph1/2 FOG-001 — a first-in-class β-catenin/TCF inhibitor — shows early promise in MSS CRC & WPAM+ solid tumors
✅ ORR 43% in non-CRC WPAM+ solid tumors
✅ No grade 4/5 TRAEs
➡️ Combo & monotherapy cohorts underway
#Targets25
Nice way to end the week. Pre-print from our team. @arnavmehta3 @JeeyunM @AnMinae, others. Support from @SU2C @AACR. @MGHCancerCenter
Differential T cell clonal dynamics underlie outcomes to frontline chemoimmunotherapy in advanced gastric cancer medrxiv.org/content/10.1101/…
Sam Klempner retweeted
A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesophageal #cancers and highlight the rapid expansion of claudin18.2-targeting drug development in solid tumors.
News & Views from @KlempnerSam and @sundar__raghav
@YaleMed @harvardmed #ADCs
nature.com/articles/s41591-0…
